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Introduction
Prostate cancer (PC) is the second most frequently 
 diagnosed cancer type and the sixth leading cause of 
cancer- related deaths in males worldwide [1]. Localized 
PC can be cured with prostatectomy and/or radiation 
therapy. However, there is no curative treatment for 
advanced and castration- resistant disease [2]. The use 
of prostate- specific antigen (PSA) for the screening of 
asymptomatic men for prostate cancer is known to 
 reduce the disease- specific mortality, but screening is 
associated with overdiagnosis [3]. Therefore, there is a 
strong  interest to find additional markers and therapeutic 
targets for the diagnosis and treatment of prostate can-
cer. MicroRNAs (miRNAs) could serve as such markers 
or as drug targets [4].
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Abstract
Micro- RNAs (miRNA) are important regulators of gene expression and often 
differentially expressed in cancer and other diseases. We have previously shown 
that miR- 193b is hypermethylated in prostate cancer (PC) and suppresses cell 
growth. It has been suggested that miR- 193b targets cyclin D1 in several 
 malignancies. Here, our aim was to determine if miR- 193b targets cyclin D1 
in prostate cancer. Our data show that miR- 193b is commonly methylated in 
PC samples compared to benign prostate hyperplasia. We found reduced miR- 
193b expression (P < 0.05) in stage pT3 tumors compared to pT2 tumors in 
a cohort of prostatectomy specimens. In 22Rv1 PC cells with low endogenous 
miR- 193b expression, the overexpression of miR- 193b reduced CCND1 mRNA 
levels and cyclin D1 protein levels. In addition, the exogenous expression of 
miR- 193b decreased the phosphorylation level of RB, a target of the cyclin 
D1- CDK4/6 pathway. Moreover, according to a reporter assay, miR- 193b targeted 
the 3’UTR of CCND1 in PC cells and the CCND1 activity was rescued by 
expressing CCND1 lacking its 3’UTR. Immunohistochemical analysis of cyclin 
D1 showed that castration- resistant prostate cancers have significantly 
(P = 0.0237) higher expression of cyclin D1 compared to hormone- naïve cases. 
Furthermore, the PC cell lines 22Rv1 and VCaP, which express low levels of 
miR- 193b and high levels of CCND1, showed significant growth retardation 
when treated with a CDK4/6 inhibitor. In contrast, the inhibitor had no effect 
on the growth of PC- 3 and DU145 cells with high miR- 193b and low CCND1 
expression. Taken together, our data demonstrate that miR- 193b targets cyclin 
D1 in prostate cancer.
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miRNAs are small, ~22 nucleotide long noncoding RNA 
molecules that were first discovered in Caenorhabditis 
elegans [5]. Since their discovery, miRNAs have been found 
to be important regulators of gene expression in other 
organisms as well [5, 6]. miRNAs modulate gene expres-
sion by binding to a complementary sequence in the 3’ 
untranslated region (3’UTR) of target messenger RNAs 
(mRNAs). The binding of a miRNA leads to the degrada-
tion of the mRNA molecule or alternatively, to the sup-
pression of mRNA translation, depending on the level of 
complementary binding [7]. Because one miRNA can have 
multiple targets and one mRNA molecule can be targeted 
by many miRNAs, miRNAs form a complex level of regu-
lation of gene expression. In addition to genetic changes 
(chromosomal rearrangements, deletions, amplifications, 
and mutations), epigenetic events such as aberrant pro-
moter hypermethylation, global hypomethylation, and 
posttranscriptional histone modification may also cause 
the dysregulation of miRNAs in cancer [7]. Several miR-
NAs are deregulated in prostate cancer and have been 
shown to affect apoptosis, cell cycle, intracellular signaling, 
DNA repair, adhesion/migration, and androgen signaling 
(reviewed in [4]).
We previously showed that hsa- miR- 193b- 3p (aka miR- 
193b) may function as an epigenetically regulated tumor 
suppressor in prostate cancer [8]. Using bisulfite sequenc-
ing we showed that miR- 193b is hypermethylated in some 
PC cell lines, with the 22Rv1 cell line being the most 
heavily methylated resulting in the loss of miR- 193b ex-
pression in the cells. Transient transfection of pre- miR- 
193b into 22Rv1 cells caused significant growth reduction 
due to a decreased fraction of cells in S- phase of the cell 
cycle.
There are several suggested target genes for miR- 193b 
in different cancers, for example, CCND1, ETS1, and 
KIT [9–16]. The cyclin D1- encoding gene, CCND1, is 
targeted by miR- 193b in hepatocellular carcinoma [10], 
melanoma [11], and pancreatic cancer [14]. Cyclin D1 
is frequently aberrantly expressed in cancer. It regulates 
the expression of genes that are involved in DNA rep-
lication and the DNA damage checkpoint. The best 
known function of cyclin D1 is most likely its catalytic 
function as a regulatory partner for the cyclin- dependent 
kinases (CDKs) 4 and 6. In response to cellular stimuli, 
cyclin D1 activates CDKs 4 and 6, which in turn phos-
phorylate various proteins, the principal substrate being 
retinoblastoma (RB) protein. When phosphorylated, RB 
releases the E2F transcription factor, which activates 
genes that are necessary for DNA synthesis and cell 
cycle progression from the G1 to S phase. In addition 
to its catalytic function, cyclin D1 also has noncatalytic 
functions, with the major function being transcriptional 
regulation [17]. In prostate cancer, cyclin D1 has been 
shown to function as a corepressor to androgen recep-
tor (AR) [18–20].
Because cyclin D1 is a suggested target of miR- 193b 
in other cancers, we aimed to study whether it is also a 
target in prostate cancer. In addition, our goal was to 
confirm the hypermethylation of miR- 193b in clinical 
prostate cancer samples.
Materials and Methods
Cell lines, xenografts, and clinical samples
The prostate cancer cell lines 22Rv1, PC- 3, LNCaP, and 
DU145 were obtained from the American Type Cell 
Collection (Manassas, VA). LAPC- 4 and VCaP cell lines 
were provided by Dr. Charles Sawyers (University of 
California at Los Angeles, Los Angeles, CA) and Dr. Jack 
Schalken (Radboud University Nijmegen Medical Center, 
Nijmegen, the Netherlands), respectively. All cell lines were 
cultured under recommended conditions. The 17 PC LuCaP 
xenografts were provided by one of the authors (R.L.V.).
All clinical samples were obtained from Tampere 
University Hospital (TAUH, Tampere, Finland). Fresh- 
frozen tissue samples, including 10 benign prostate 
 hyperplasias (BPH), 26 untreated prostatectomy specimens, 
and nine castration- resistant tumors (CRPC), were used 
to study miR- 193b methylation, whereas 78 hormonally 
untreated PC prostatectomy specimens (Table S1) were 
used to study miR- 193b expression. BPH samples were 
obtained from transurethral resection (TURP) or (cysto)
prostatectomies from patients with BPH or bladder cancer. 
Untreated cancer samples were obtained from prostatec-
tomies and CRPC samples from TURP. The samples used 
in this study were histologically examined to contain >70% 
cancerous or hyperplastic tissue. For cyclin D1 immuno-
histochemical analysis, a total of 267 formalin- fixed prostate 
cancer specimens (198 from prostatectomies and 69 CRPC 
samples) were used to construct tissue microarrays (TMAs; 
Table S2). Ethics Committee of Tampere University 
Hospital and National Authority for Medicolegal Affairs 
have approved the use of clinical tumor material.
DNA and RNA extraction from clinical 
samples
For the methylation analysis, freshly frozen tissue blocks 
were cut into 10 × 20- micrometer sections using a cry-
otome. DNA was isolated using an AllPrep RNA/DNA 
minikit (Qiagen, Valencia, CA) according to the manu-
facturer’s protocol. For miR- 193b expression analysis and 
arrays, RNA was isolated using Trizol® reagent (Invitrogen, 
Life Technologies Corporation, Carlsbad, CA) according 
to the manufacturer’s protocol.
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Microarrays
miRNA and mRNA expression data from cell lines was 
produced using Agilent Tehcnologies’ (Santa Clara, CA) 
miRNA microarray system (version 1 array containing 470 
human and 64 viral miRNAs) [8] and Whole Human Genome 
Kit (4 × 44k) (Agilent Tehcnologies, Santa Clara, CA), re-
spectively. For LuCaP xenografts Affymetrix (Santa Clara, 
CA) HG U133 Plus 2.0 microarray was used. The arrays 
were done  according to the manufacturer’s protocols.
Cell transfection and cotransfection
To determine the effect of miR- 193b expression on cyclin 
D1, RB, and pRB levels, 22Rv1 cells were transfected with 
a final concentration of 5 nmol/L pre- miR- 193b or scram-
bled control using INTERFERin transfection reagent 
(Polyplus- transfection, Illkirch, France) according to the 
manufacturer’s instructions. The cells were collected 3 days 
after transfection. miRNA precursors were purchased from 
Ambion (Applied Biosystems/Ambion, Austin, TX).
For the Cyclin D1 rescue and cell cycle experiment, 
22Rv1 cells were cotransfected with 10 μg of plasmid, 
pCMV- CCND1 lacking a 3’UTR (Plasmid 19927; Addgene, 
Cambridge, MA), or the control plasmid pCMV6- AC- GFP 
(OriGene Technologies, Rockville, MD) along with either 
pre- miR- 193b or pre- miR- scramble at a final concentra-
tion of 10 nmol/L, using jetPRIME transfection reagent 
(Polyplus- transfection). The cells were collected 2 days 
after transfection.
Flow cytometric analysis
Cells were harvested by trypsinization, washed with 
phosphate- buffered saline (PBS) and fixed in cold 70% EtOH. 
Ethanol was aspirated, and the cells were washed and 
 rehydrated with PBS. Staining was performed with propidium 
iodide (Sigma-Aldrich, St. Louis, MO), and cell cycle 
profiles were analyzed with Accuri C6 Flow cytometer.
Luciferase reporter assay
For the luciferase reporter assay, the pSGG- 3UTR plas-
mid was purchased from SwitchGear Genomics (Menlo 
Park, CA). The plasmid contains a luciferase gene fused 
with the 3’UTR of CCND1. 22Rv1 cells were cotrans-
fected with the 3’UTR plasmid, a control plasmid- 
containing Renilla luciferase and pre- miR- 193b or 
pre- miR- scramble using Lipofectamine™ 2000 transfec-
tion reagent (Invitrogen) according to the manufacturer’s 
instructions. Firefly and Renilla luciferase activities were 
measured 24 h after transfection using the Dual- Glo 
Luciferase Assay System (Promega, Madison, WI). Renilla 
luciferase values were used for data normalization. The 
luciferase assay was performed in quadruplicate, and 
repeated four times.
Western Blot
Nuclear and cytoplasmic proteins for RB and pRB western 
blots and total protein for cyclin D1 western blots were 
isolated as described previously [21, 22]. A total of 20 μg 
of proteins were separated on 8% (RB, pRB) and 10% 
(Cyclin D1) SDS- PAGE gels and blotted to a PVDF mem-
brane (Immobilon- P, Millipore Corp., Billerica, MA). The 
membranes were incubated with primary antibodies against 
phospho- Rb (Ser795, 1:1000, Cell Signaling, Danvers, MA), 
Rb (C- 15: sc- 50, 1:500; Santa Cruz Biotechnology, Inc., Dallas, 
TX) or cyclin D1 (clone SP4, 1:100; Dako, Glostrup, Denmark) 
and with antibodies against fibrillarin (C13C3, 1:4000; Cell 
Signaling) or actin (pan AB- 5 clone ACTN05, 1:400; Lab 
Vision Corp., Fremont, CA). After secondary antibody in-
cubation (anti- rabbit- HRP for phospho- RB, RB, cyclin D1 
and fibrillarin, and anti- mouse- HRP for Actin; 1:3000, Dako), 
the proteins were visualized by autoradiography.
Immunohistochemistry
Antibodies against cyclin D1 (dilution 1:100, clone SP4; 
Dako) and Ki- 67 (dilution 1:500, MM1; Leica Biosystems 
Newcastle Ltd., Newcastle upon Tyne, UK) were used 
with a Power Vision+ Poly- HRP IHC kit (ImmunoVision 
Technologies Co., Hillsborough, CA) according to the 
manufacturer’s instructions and as described by Leinonen 
et al. [23]. The slides were scanned with an Aperio 
ScanScope XT scanner (Leica Microsystems GmbH, 
Wetzlar, Germany). The virtual microscope [24, 25] and 
the ImmunoRatio web  application [26] were used to score 
the cyclin D1- staining intensity (0–1 = negative and weak, 
2 = moderate, and 3 = strong) in a blinded fashion.
Quantitative real- time RT- PCR
For miR- 193b q- RT- PCR, a TaqMan microRNA Assay 
(Applied Biosystems, Foster City, CA) and the CFX96 
q- RT- PCR detection system (Bio- Rad Laboratories Inc., 
Hercules, CA) were used according to the manufacturers’ 
recommendations. miRNA expression was normalized to 
RNU6B expression. For CCND1 q- RT- PCR, first- strand 
complementary DNA synthesis was performed from total 
RNA using AMV reverse transcriptase (Finnzymes Inc., 
Espoo, Finland) according to the manufacturer’s instruc-
tions. The expression of CCND1 was measured with Maxima 
SYBR Green (Fermentas Inc., Burlington, ON, Canada) 
and the CFX96 q- RT- PCR detection system (Bio- Rad 
Laboratories Inc.) and was normalized to the β- Actin 
1420 © 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. 
 
K. M. Kaukoniemi et al.miR-193b Targets Cyclin D1 in PC
reference gene. The primer sequences used for the CCND1 
and β- Actin q- RT- PCR were: CyclinD1for 5’- CCCTCGGTG 
GGTCCTACTTCAA- 3’, CyclinD1rev 5’- TGGCATTTTGG 
AGAGGAAGT- 3’, and Bactinf4 5’- TGGGACGACATGGAG 
AAAAT- 3’, Bactinr4 5’- AGAGGCGTACAGGGATAGCA- 3’.
miR- 193b methylation analysis
Methylated DNA was enriched using MethylMiner™ 
Methylated DNA Enrichment Kit (Invitrogen) according to 
the manufacturer’s instructions. Briefly, 2 μg of genomic 
DNA was fragmented by sonication. Methylated DNA was 
enriched by binding to magnetic beads coated with the 
methyl- CpG- binding domain of the human MBD2 protein 
(Methyl- CpG Binding Domain Protein 2) and eluted as a 
single fraction using 2 M NaCl. Finally, the DNA was 
ethanol- precipitated and resuspended in 50 μL of DNase- free 
water. For q- PCR, iQTM SYBR® Green supermix and CFX96 
q- RT- PCR detection system (Bio- Rad Laboratories Inc.) were 
used. The sequences of the primers used in the q- PCR were: 
miR- 193b_DMR_f1 5’- TGGCGTTTCTGG TTTCTCTT- 3’ 
and miR- 193b_DMR_r2 5’- CGCACCTTTTCTCCTCAT 
TT- 3’. Each sample was run in duplicate. The methylation 
status of miR- 193b was calculated from the elution- fraction 
signal in relation to the total q- PCR signal.
Growth curves
For growth analysis with the CDK4/6 inhibitor PD0332991 
(Selleck Chemicals, Houston, TX), the 22Rv1 cells were 
seeded in 24- well plates in quadruplicate for each inhibi-
tor concentration. The following day, the cells were imaged 
(day 0), and then treated with 0 nmol/L, 100 nmol/L, 
500 nmol/L, or 2000 nmol/L inhibitor. The medium was 
replaced every other day with fresh medium containing 
the inhibitor. The cells were imaged daily with an Olympus 
IX71 microscope with the OASIS automation control sys-
tem and Surveyor imaging software version 5.5.5.26 
(Objective Imaging Ltd., Cambridge, UK). Cell growth 
was analyzed by measuring the cell surface area with an 
in- house macro and ImageJ software (NIH, Bethesda, MD). 
The experiments were repeated three times.
Statistical analysis
An unpaired t test was used to calculate the significant 
difference in cell cycle analysis and in luciferase activity 
between the pre- miR- scramble and pre- miR- 193b trans-
fected samples as well as the difference in miR- 193b ex-
pression between differentially staged prostatectomy 
tumors. The paired t test was used to calculate the P- value 
of the growth curve assays on the last day of the experi-
ment. Fisher’s exact test was used to assess the significant 
difference in miR- 193b methylation in clinical samples. 
Fisher’s exact, chi- square, Mann–Whitney U, and unpaired 
t tests were used to analyze the association between clin-
icopathologic variables. A P- value <0.05 was considered 
significant. Spearman’s correlation was used to study the 
correlation of miR- 193b and CCND1 expression in cell 
lines and xenograft samples in microarray analysis.
Results
We have previously shown that miR- 193b is strongly hy-
permethylated in 22Rv1 cells and moderately methylated 
in VCaP cells but is not methylated in LAPC- 4, LNCaP, 
DU145, PC- 3, EP156T, or PrEC cells, as determined by 
bisulfite sequencing [8]. In addition, we sequenced five 
untreated and four CRPC clinical specimens and found 
increased methylation [8]. Here, we wanted to confirm 
hypermethylation of miR- 193b in clinical specimens. We 
recently performed genome- wide methylation analysis of 
methylation by MeDIP- sequencing (unpubl. data) and 
found that the most differentially methylated genomic 
region in proximity to miR- 193b is 16:14396975–14397475 
(GRCh37), which is located 349 bp upstream of the miR- 
193b gene. Here, we measured the methylation of miR- 
193b in that region in BPH (n = 10), PC (n = 26) and 
CRPC (n = 9) samples using MethylMiner- qPCR. The 
samples were classified as methylated if they showed more 
than 20% methylation. According to our analysis, miR- 
193b was significantly more methylated in cancer than 
in BPH (P < 0.0001; Fig. 1A).
Next, we measured the expression of miR- 193b in a 
larger set (n = 78) of prostatectomy samples and found 
that the expression was lower (P < 0.05) in stage pT3 
tumors than in stage pT2 tumors (Fig. S1). However, we 
did not find an association between miR- 193b expression 
and the Gleason score or progression- free survival (data 
not shown).
Because CCND1 is a suggested target of miR- 193b target 
in hepatocellular and pancreatic carcinoma and melanoma 
[10, 11, 14], we aimed to determine if it is also a target 
in prostate cancer. The expression levels of miR- 193b and 
CCND1 were obtained using expression microarrays of PC 
cell lines and xenograft samples. The array data showed a 
negative correlation between miR- 193b and CCND1 expres-
sion in the cell lines (Fig. 1B, r = −0.7714) as well as in 
the xenograft samples (Fig. 1C, r = −0.2522). We then 
studied the expression of CCND1 mRNA and protein levels 
in 22Rv1 cells transiently transfected with pre- miR- 193b. 
A marked reduction in the CCND1 expression at both the 
mRNA (Fig. 2A) and protein (Fig. 2B) level was detected 
in cells transfected with pre- miR- 193b compared to the 
scrambled pre- miR transfected cells. Similar to 22Rv1 cells, 
the Cyclin D1 protein expression was diminished also in 
1421© 2015 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  
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VCaP cells transiently transfected with pre- miR- 193b (Fig. 
S2). In addition, a marked reduction was detected in phos-
pho- RB protein level in nuclear protein fractions (Fig. 2C).
To confirm that miR- 193b binds to the 3’UTR - region 
of the CCND1 gene in prostate cancer cells, we performed 
a luciferase reporter assay. A pSGG- luciferase plasmid 
containing CCND1 3’UTR at the 3’ end of the luciferase 
gene was transfected together with either pre- miR- 193b 
or pre- miR- scramble into 22Rv1 cells which express low 
levels of miR- 193b endogenously. The inhibition of 
 luciferase activity was observed when the cells were trans-
fected together with the plasmid and pre- miR- 193b 
(P < 0.05) but not with pre- miR- scramble (Fig. 3A), 
confirming that miR- 193b targets the 3’UTR of CCND1.
To evaluate the significance of CCND1 as a miR- 193b 
target, a rescue experiment was performed. We used the 
phosphorylation of RB as a measure of cyclin D1 activity. 
Phospho- RB levels decreased in cells transfected with pre- 
miR- 193b. When the cells were cotransfected with pre- 
miR- 193b and the pCMV- CCND1 plasmid lacking the 
3’UTR of CCND1, no such reduction in phospho- RB levels 
was observed (Fig. 3B). Similarly, transient pre- miR- 193b 
transfection caused a reduction in the number of cells 
in S and G2/M phase fractions of cell cycle, whereas there 
was no difference in cells cotransfected with pre- miR- 193b 
and CCND1 lacking 3’UTR (Fig. S3).
Because cyclin D1 regulates the activity of CDK4/6, we 
treated PC cell lines with the CDK4/6 inhibitor PD0332991 
at different concentrations and measured the effect on 
prostate cancer cell growth. 22Rv1 and VCaP cells, which 
express low levels of miR- 193b and high levels of CCND1, 
Figure 1. miR- 193b is methylated in cancer samples and has inverse expression pattern compared to CCND1. (A) miR- 193b methylation in clinical 
samples (BPH, PC, and CRPC) was assessed by MethylMiner- qPCR. miR- 193b and CCND1 expressions were studied by miRNA and mRNA microarray 
(B) in prostate cancer cell lines and (C) xenograft samples. Spearman correlation coefficiencies are given. BPH, benign prostate hyperplasias; CRPC, 
castration- resistant tumors; PC, prostate cancer.
A B
C
Figure 2. miR- 193b overexpression reduces the expression of CCND1, 
the level of Cyclin D1 protein and phosphorylation level of retinoblastoma 
(RB). 22Rv1 prostate cancer cells were transfected with pre- miR- 193b or 
pre- miR- control. (A) Expression levels of CCND1 mRNA was measured 
using q- RT- PCR. Western blot analysis was used to detect protein 
expression of (B) Cyclin D1 from total proteins and (C) phosphorylation 
level of RB protein from nuclear protein fraction. Actin and fibrillarin 
antibodies were used as loading controls.
A
B C
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showed significant growth suppression at a 500 nmol/L 
concentration (P < 0.05; Fig. 4A, B), whereas the various 
concentrations of the inhibitor had little effect on the 
growth of DU145 (Fig. 4C), LNCaP LAPC- 4 or PC- 3 
cells, which express high levels of miR- 193b and low levels 
of CCND1 (Fig. S4A–C). Figure S4D shows that the  vehicle, 
dimethylsulfoxide (DMSO), has no effect on the cell growth 
of 22Rv1 cells at 0.4% concentration.
To study the expression of cyclin D1 in clinical samples, 
we performed an immunohistochemical analysis on TMAs. 
The analysis showed that the CRPC samples expressed 
higher levels of cyclin D1 compared to PC samples 
(P = 0.0237; Table 1). In prostatectomy samples, the cyclin 
D1 staining intensity was not associated with Gleason 
score, pT stage, or diagnostic PSA levels. However, there 
was strong positive association between cyclin D1 and 
the proliferation marker Ki- 67 (P < 0.0001) in the pros-
tatectomy cohort. CRPC cells expressing high levels of 
cyclin D1 had increased Ki- 67 values, although the as-
sociation was not statistically significant.
Discussion
Here, we confirmed the hypermethylation of miR- 193b gene 
in prostate cancer. The hypermethylation of miR- 
193b leads to reduced expression, as we have previously 
shown [8]. Because miRNAs regulate the expression of 
protein- coding genes, the key question is which proteins 
are targeted by miR- 193b in prostate cancer. CCND1 is a 
target in hepatocellular and pancreatic carcinoma, as well 
as in melanoma [10, 11, 14]. We have previously shown 
that the overexpression of miR- 193b reduces the prolifera-
tion of prostate cancer cells due to a decreased number 
of cells in S- phase of the cell cycle [8], suggesting that 
Figure 4. CDK 4/6 inhibitor PD0332991 suppresses the growth of (A) 
22Rv1 and (B) VCaP cells but not (C) DU145 cells. Cells were treated 
with 0, 100, 500, and 2000 nmol/L concentrations of the inhibitor and 
growth was followed for 5 to 6 days. Each concentration was done in 
quadruplicates and each experiment was done in triplicates, averages 
from experiments ±SEM are shown. P- values of growth differences 
between different concentrations on day 5 or 6 were calculated using 
paired t- test, *P- value <0.05, **P- value <0.01.
A
B
C
Figure 3. miR- 193b targets CCND1 3’UTR. (A) Luciferase experiment was 
performed in 22Rv1 cells cotransfected with pSGG- plasmid containing 
CCND1 3’UTR, Renilla luciferase plasmid, and pre- miR- 193b or pre- miR- 
control. Values were normalized against Renilla luciferase activity. The 
means of four experiments ±SEM are shown. *P- value <0.05 (B) Western 
blot analysis of pRB in 22Rv1 cells transfected with pCMV- CCND1 
plasmid lacking CCND1 3’UTR together with miR- scramble or miR- 193b. 
Fibrillarin antibody was used as loading control for nuclear proteins.
A
B
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CCND1 could also be a target for miR- 193b in prostate 
cancer.
We showed that the expressions of miR- 193b and CCND1 
are inversely correlated in prostate cancer cell lines and 
xenografts. Subsequently, we demonstrated reduced mRNA 
and protein expression of CCND1 in 22Rv1 cells tran-
siently transfected with pre- miR- 193b. Using a reporter 
assay, we confirmed that miR- 193b targets the 3’UTR of 
the CCND1 gene in 22Rv1 prostate cancer cells. 
Concordantly, Chen et al. [11]. and Xu et al. [10]. have 
previously shown by luciferase assay that miR- 193b targets 
the CCND1 3’UTR in Malme- 3M malignant melanoma 
and HepG2 hepatocellular carcinoma cells. In addition, 
we performed a rescue experiment, in which we cotrans-
fected miR- 193b into 22Rv1 cells with and without the 
pCMV- CCND1 plasmid lacking the 3’UTR of CCND1. 
These results show that CCND1 is a bona fide target of 
miR- 193b in prostate cancer cells.
To assess the relevance of cyclin D1 targeting by miR- 
193b in prostate cancer cells, we studied the activity of 
the cyclinD1–RB pathway in the regulation of the G1/S 
transition in the cell cycle. The transfection of 22Rv1 
cells with miR- 193b reduced the level of phospho- RB, in 
accordance with the known function of cyclin D1 in the 
regulation of RB phosphorylation. In addition, the phos-
phorylated RB protein levels were rescued in pCMV- 
CCND1/miR- 193b cells to those of the control cells. Finally, 
when prostate cancer cell lines were treated with the 
CDK4/6 inhibitor PD0332991, the cell lines responded to 
the treatment according to miR- 193b expression/methyla-
tion status and cyclin D1 levels. Those with low miR- 193b 
and high cyclin D1 (22Rv1, VCaP) responded to the drug 
with growth inhibition, while the others did not. These 
results demonstrate that the downregulation of cyclin D1 
by miR- 193b is functionally relevant for prostate cancer 
cell growth.
To assess the clinical significance of cyclin D1, we stained 
TMAs and found that the expression of cyclin D1 is higher 
in CRPC (n = 69) compared to hormone- naïve PC 
(n = 198). Previously, Drobnjak et al. [27]. showed in-
creased cyclin D1 staining in 22 CRPC bone metastases 
compared to 86 primary PC tumors. In our prostatectomy 
samples, the expression was strongly associated with pro-
liferation but not with Gleason score, pathological status, 
PSA value, or age at diagnosis. This is in line with previ-
ous studies showing that cyclin D1 expression is associated 
with the proliferation marker Ki- 67 but not with other 
clinicopathological variables [27–31].
Because it is known that one gene can be targeted by 
several miRNAs and that cyclin D1 is a key regulator of 
the cell cycle G1/S transition, it is not surprising that 
CCND1 has been suggested to be a target of more than 
one miRNA in prostate cancer. Bonci et al. reported that 
miR15- a and 16- 1 interact directly with the 3’UTR of 
CCND1 and reduce cyclin D1 protein expression, thereby 
reducing prostate cell proliferation [32]. However, the 
function of CCND1 targeting by these three miRNAs is 
altered by different mechanisms in prostate cancer. miR- 
193b is epigenetically regulated and silenced by methylation 
[8], whereas the function of miRs 15- a and 16- 1 is dis-
rupted by deletions in the encoding chromosomal region 
13q14 [32]. We have previously reported a homozygous 
deletion of the miR15- a and 16- 1 locus in prostate cancer, 
although the frequency is relatively low [33].
In addition to CCND1, there are several other suggested 
targets for miR- 193b, such as YWHAZ, PLAU (aka uPA), 
and KIT in different cancer types [9–16]. Xie et al. [34]. 
showed that the knockdown of cystic fibrosis transmem-
brane conductance regulator (CFTR) led to the suppression 
of miR- 193b expression. They also showed that the forced 
overexpression of miR- 193b completely abrogated elevated 
urokinase- type plasminogen activator (uPA) activity after 
CFTR- knockdown in PC- 3 cells, suggesting that the tumor- 
suppressing effect of CFTR is mediated through the miR- 
193b- uPA axis. However, it should be noted that miR- 193b 
expression is low in 22Rv1 and VCaP cells [8], which 
do not express uPA [35, 36], suggesting that uPA is not 
the major target of miR- 193b in prostate cancer.
In conclusions, we have demonstrated that the over-
expression of cyclin D1 in prostate cancer is driven, at 
least partly, by the reduced expression of miR- 193b. The 
mechanism for miR- 193b suppression is the 
Table 1. Association of clinicopathological variables with Cyclin D1 
expression.
Variable
Cyclin D1 expression
P
Negative  
(0/1)
Positive  
(2–3)
Prostatectomy specimens, n (%) 74 (37) 124 (63)
Locally recurrent CRPCs, n (%)1 20 (29)  49 (71) 0.0237
Prostatectomy specimens
Gleason score, n (%)1
<7 24 (33)  46 (37)
  7 38 (52)  60 (48)
>7 11 (15)  19 (15) 0.8337
pT Stage, n (%)2
pT2 54 (75)  88 (72)
pT3 18 (25)  35 (28) 0.6216
PSA ng/mL (mean ± SD)3 20.0 ± 31.5 14.3 ± 11.3 0.9786
Age (mean ± SD)4 62.6 ± 5.2 63.2 ± 4.9 0.4167
Ki- 67 (mean ± SD)   7.1 ± 7.0 13.6 ± 14.5 <0.0001
Locally recurrent CRPCs, n (%)3
Ki- 67 (mean ± SD) 13.2 ± 9.3 20.7 ± 15.8 0.0950
1Chi- square test.
2Fisher’s exact test.
3Mann–Whitney U- test.
4Unpaired t test.
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hypermethylation of the DMR upstream of the miR- 193b 
gene. Additional studies are warranted to translate these 
findings to clinical benefits. For example, the restoration 
of miR- 193b expression could theoretically reduce the 
proliferation of prostate cancer cells. Alternatively, the loss 
of miR- 193b expression could indicate the sensitivity of 
prostate cancer cells to cyclin D1 inhibition.
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